| Revenue growth | 6.4% YoY for FY26; underlying growth 10% excluding access markets. |
|---|---|
| Margins | EBITDA margins expanded 140bps YoY to 19%; targeting 20% upwards. |
| Demand visibility | Strong in Ex-U.S. markets; U.S. growth expected H2 FY27 onwards. |
| Management confidence | High; citing structural shift to diversified, resilient portfolio and operational discipline. |
Growth
FY26 revenue grew 6.4% to ₹48,587M; EBITDA grew 15% to ₹9,250M with 19% margins. Operational PAT rose 50%.
Outlook
Guided U.S. revenue of $375M-$400M by FY28. Targeting EBITDA margins 20%+ and gross margins 58-60%.
Risks
Geopolitical environment, logistical cost spikes (₹200M in Q4), and a weak U.S. flu season impacted seasonal revenue.
Earnings Call filed with NSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,088.70
- Market cap
- ₹10,035 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.4×Sector 47.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Business Update
Strides Pharma Science received a USFDA Establishment Inspection Report (EIR) for its Bengaluru facility. This confirms the successful closure of the recent cGMP inspection.
Strides Pharma Science Annual General Meeting
Strides Pharma Science Ltd held its 35th Annual General Meeting on August 14, 2026. The meeting transacted ordinary and special business items.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science Results Update
Strides Pharma Science reported a 13% YoY revenue growth to ₹1,265.4 Crore for Q1FY27. EBITDA grew 5.4% to ₹229.8 Crore despite geopolitical cost disruptions.
- Value
- ₹1,265 Cr